Literature DB >> 20880268

Prevalence of Parkinson's disease and atypical parkinsonian syndromes in a rural Japanese district.

Y Osaki1, Y Morita, T Kuwahara, I Miyano, Y Doi.   

Abstract

OBJECTIVES: To investigate the prevalence of Parkinson's disease (PD) and atypical parkinsonian syndromes (APS) in a rural Japanese district.
METHOD: Collaboration with the medical institutions, the long-term care insurance system facilities, and the public health office.
RESULTS: The crude prevalence rates were 175 per 100,000 (95% CI: 143-206) for PD, 18 (8-28) for progressive supranuclear palsy, 17 (7-26) for multiple system atrophy (MSA), and 9 (2-16) for corticobasal degeneration. The age-adjusted prevalence rates were 109 per 100,000 (88-134), 10 (2-17), 13 (4-21), and 6 (0-12), for each condition. There was a preponderance of women with PD and of men with APS. Nine of the 116 PD patients and 7 of the 29 APS patients were newly diagnosed in this study.
CONCLUSIONS: There are high prevalence rates for PD and APS and suboptimal recognition of APS. This is the first epidemiological prevalence study of MSA from Japan.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2010        PMID: 20880268     DOI: 10.1111/j.1600-0404.2010.01442.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  16 in total

1.  Real-world pharmacological treatment patterns of patients with young-onset Parkinson's disease in Japan: a medical claims database analysis.

Authors:  Sachiko Kasamo; Masato Takeuchi; Masashi Ikuno; Yohei Kawasaki; Shiro Tanaka; Ryosuke Takahashi; Koji Kawakami
Journal:  J Neurol       Date:  2019-05-10       Impact factor: 4.849

2.  Prevalence and Clinical Features of Idiopathic Parkinson's Disease in Western Turkey.

Authors:  Sibel Güler; Ayşe Caylan; F Nesrin Turan; Nezih Dağdeviren
Journal:  Noro Psikiyatr Ars       Date:  2021-07-10       Impact factor: 1.066

3.  Systematic Review of Prevalence Studies of Progressive Supranuclear Palsy and Corticobasal Syndrome.

Authors:  Diane M A Swallow; Cindy S Zheng; Carl E Counsell
Journal:  Mov Disord Clin Pract       Date:  2022-06-28

Review 4.  Genetics Underlying Atypical Parkinsonism and Related Neurodegenerative Disorders.

Authors:  Sonja W Scholz; Jose Bras
Journal:  Int J Mol Sci       Date:  2015-10-16       Impact factor: 5.923

5.  Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010.

Authors:  Sachiko Nakaoka; Tatsuro Ishizaki; Hisashi Urushihara; Toshihiko Satoh; Shunya Ikeda; Mitsutoshi Yamamoto; Takeo Nakayama
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

6.  Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade.

Authors:  Hiroshi Takigawa; Michio Kitayama; Kenji Wada-Isoe; Hisanori Kowa; Kenji Nakashima
Journal:  Brain Behav       Date:  2016-10-11       Impact factor: 2.708

7.  Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database.

Authors:  Emma Viscidi; Irene Litvan; Tien Dam; Maneesh Juneja; Li Li; Henry Krzywy; Susan Eaton; Susan Hall; Joseph Kupferman; Günter U Höglinger
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.003

8.  Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy.

Authors:  James W Wheless
Journal:  Epilepsy Behav Case Rep       Date:  2015-08-12

9.  A Cross-Sectional Study on Socioeconomic Systems Supporting Outpatients With Parkinson's Disease in Japan.

Authors:  Aiko Matsushima; Akihisa Matsumoto; Fumio Moriwaka; Sanae Honma; Kazunori Itoh; Keiko Yamada; Shun Shimohama; Hirofumi Ohnishi; Junichi Matsushima; Mitsuru Mori
Journal:  J Epidemiol       Date:  2015-12-05       Impact factor: 3.211

10.  Causes of Death in Chinese Patients with Multiple System Atrophy.

Authors:  LingYu Zhang; Bei Cao; Yutong Zou; Qian-Qian Wei; RuWei Ou; Wanglin Liu; Bi Zhao; Jing Yang; Ying Wu; HuiFang Shang
Journal:  Aging Dis       Date:  2018-02-01       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.